Serge Holz

Serge Holz

Auto-generated profile, based on publicly available information

Serge Holz

Urology Department, Ambroise Paré Hospital, Mons, Belgium

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2014 in Prostate Cancer
Verified
Journal Article
Open access
PDF file
KLKsenija Limani
Ksenija Limani
FAFouad Aoun
Fouad Aoun
SHSerge Holz
Serge Holz
MPMarianne Paesmans
Marianne Paesmans
APAlexandre Peltier
Alexandre Peltier
RVRoland van Velthoven
Roland van Velthoven
Objectives. To assess the treatment outcomes of a single session of whole gland high intensity focused ultrasound (HIFU) for patients with localized prostate cancer (PCa).Methods. Response rates were defined using the Stuttgart and Phoenix criteria. Complications were graded according to the Clavien score.Results. At a median follow-up of 94months, 48 (44.4%) and 50 (46.3%) patients experienced biochemical recurrence for Phoenix and Stuttgart definition, respectively. The 5- and 10-year actuarial biochemical recurrence free survival rates were 57% and 40%, respectively. The 10-year overall survival rate, cancer specific survival rate, and metastasis free survival rate were 72%, 90%, and 70%, respectively. Preoperative high risk category, Gleason score, preoperative PSA, and postoperative nadir PSA were independent predictors of oncological failure. 24.5% of patients had self-resolving LUTS, 18.2% had urinary tract infection, and 18.2% had acute urinary retention. A grade 3b complication occurred in 27 patients. Pad-free continence rate was 87.9% and the erectile dysfunction rate was 30.8%.Conclusion. Single session HIFU can be alternative therapy for patients with low risk PCa. Patients with intermediate risk should be informed about the need of multiple sessions of HIFU and/or adjuvant treatments and HIFU performed very poorly in high risk patients.

1 September 2017 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
SHSerge Holz
Serge Holz
SASimone Albisinni
Simone Albisinni
JGJacques Gilsoul
Jacques Gilsoul
MPMichel Pirson
Michel Pirson
VDVéronique Duthie
Véronique Duthie
TRThierry Roumeguère
Thierry Roumeguère
Objective: To assess the risk factors associated with recurrence, progression and survival in high-risk non-muscle-invasive bladder cancer (NMIBC) patients treated with bacillus Calmette–Guérin (BCG) and validate the European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) scores. Patients and methods: We retrospectively analyzed all BCG-treated NMIBC patients from 1998 to 2012. Multiple variables were tested as risk factors for recurrence-free survival and progression-free survival (PFS). Variables included age, sex, grade, stage, tumor size, number of tumors, carcinoma in situ (CIS), recurrence status, BCG strain used, smoking status, use of re-staging transurethral resection and use of single immediate postoperative instillation. We also tested the accuracy of EORTC and CUETO scores in predicting recurrence and progression. Results: Overall, 123 patients were analyzed. Median (interquartile range) follow-up was 49 months. The 5-year overall survival, cancer-specific survival, recurrence-free survival and PFS were 75.0%, 89.3%, 59.4% and 79.2%, respectively. On univariate analysis, multiple tumors (≥3), concomitant CIS and smoking influenced recurrence. Regarding progression, multiple tumors, concomitant CIS and Connaught strain (vs Tice) negatively influenced PFS on univariate and multivariate analyses were independent prognostic factors. CUETO scores were accurate, with a slight overestimation, while EORTC score was not predictive of recurrence or progression. Conclusion: In this study, CIS and tumor multiplicity were unfavorable predictors of recurrence and progression in patients with NMIBC receiving BCG. CUETO model was superior to EORTC risk tables in predicting recurrence and progression in our BCG-treated patient population. Nonetheless, both scores overestimated recurrence and progression rates. Prospective trials are needed to validate our findings.

1 December 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
SHSerge Holz
Serge Holz
LTLorenzo Tosco
Lorenzo Tosco
MAMurat Akand
Murat Akand
AVAnnelies Verbiest
Annelies Verbiest
BBBenoit Beuselinck
Benoit Beuselinck
SJSteven Joniau
Steven Joniau

28 July 2023 in Radiology Case Reports
Verified
Journal Article
Open access
MBMoncef Al Barajraji
Moncef Al Barajraji
MCMathieu Coscarella
Mathieu Coscarella
SHSerge Holz
Serge Holz
IMIlan Moussa
Ilan Moussa
MNMichel Naudin
Michel Naudin
NBNicolas Brassart
Nicolas Brassart
Renal artery pseudoaneurysm may develop after laser flexible ureteroscopy stone lithotripsy (FURSL). Typical symptoms include flank pain, persistent hematuria, delayed refractory anemia, or hemorrhagic shock in case of pseudoaneurysm rupture. This complication of laser FURSL is very rare with only five cases reported in the literature as of April 2023, of which one involved Thulium laser. We report the case of a 65-year-old man with recurrent renal lithiasis who underwent FURSL using Thulium fibered laser (TFL) for 8 mm stone of left kidney upper pole. Persistent hematuria developed postoperatively, secondary to a pseudoaneurysm from a segmental branch of the left renal artery. It was diagnosed on arteriography performed for sudden hemorrhagic shock 27 days after surgery. Selective embolization with metallic micro-coils resolved hematuria. Although laser FURSL is often uncomplicated and TFL is regarded as safe, this complication should be suspected when refractory hematuria or hemodynamic instability follows the procedure. We report this case to add support to the current literature and outline procedural risk factors and useful precautions during the procedure.

1 November 2017 in Current Urology
Verified
Journal Article
Open access
PDF file
AOAdama Ouattara
Adama Ouattara
TOTiago Ribeiro de Oliveira
Tiago Ribeiro de Oliveira
SHSerge Holz
Serge Holz
HBHannes Van Den Bossche
Hannes Van Den Bossche
DSDavid Strybol
David Strybol
Steven JoniauSteven Joniau
Steven Joniau
We report a case of a 65-year-old male patient with high-risk prostate cancer, re-staged with 11C-choline positron emission tomography/computed tomography (PET/CT) for prostate specific antigen recurrences 3 years after radical prostatectomy and adjuvant radiation therapy. In addition to 2 suspicious presacral lymph nodes which were resected and proven to be metastatic, PET/CT revealed a very high uptake in a calcified thyroid nodule. Evaluation with fine needle aspiration was suspicious for thyroid carcinoma and the patient underwent total thyroidectomy, confirming a non-metastatic encapsulated follicular variant of papillary thyroid carcinoma. To our knowledge, this is the first report of a thyroid cancer diagnosed with 11C-choline PET/CT for prostate cancer staging.

1 February 2016 in Progrès en Urologie
Verified
Journal Article
Closed access
SHS. Holz
S. Holz
JCJ.L. Sotorres Cabanillas
J.L. Sotorres Cabanillas
FLF. Legrand
F. Legrand
JGJ. Gilsoul
J. Gilsoul
MPM. Pirson
M. Pirson
TRThierry Roumeguère
Thierry Roumeguère